Trial Profile
A randomized phase IB/IIA study of CApecitabine plus Radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Radium 223 chloride (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARBON
- Sponsors Bayer HealthCare
- 15 Jan 2020 Trial design and study protocol for a phase IB/IIA randomised controlled trial has been published in the Trials.
- 19 Mar 2018 Status changed from recruiting to completed.
- 19 May 2016 Status changed from not yet recruiting to recruiting.